Effect of Oral Colestimide on the Elimination of High-dose Methotrexate in Patients With Primary Central Nervous System Lymphoma —Two Case Reports—

Keishi MAKINO; Masato KOCHI; Hideo NAKAMURA; Jun-ichiro KURODA; Yoshiteru HONDA; Yukitaka USHIO; Jun-ichi KURATSU

doi:10.2176/nmc.45.650

Case Reports

Effect of Oral Colestimide on the Elimination of High-dose Methotrexate in Patients With Primary Central Nervous System Lymphoma

—Two Case Reports—

Keishi MAKINO, Masato KOCHI, Hideo NAKAMURA, Jun-ichiro KURODA, Yoshiteru HONDA, Yukitaka USHIO, Jun-ichi KURATSU

Author information

Keywords: malignant lymphoma, colestimide, methotrexate

JOURNAL OPEN ACCESS

2005 Volume 45 Issue 12 Pages 650-652

DOI https://doi.org/10.2176/nmc.45.650

Details

Abstract

Delayed methotrexate (MTX) elimination occurred in two patients with primary central nervous system lymphoma undergoing high-dose MTX treatment. Oral administration of the anion exchange resin colestimide, which binds MTX effectively in vitro, effectively accelerated MTX elimination. Colestimide probably interrupts the enterohepatic circulation, and is a potential oral antidote to MTX toxicity.

Corresponding author

Register with J-STAGE for free!